Dr. Sunil Aggarwal appeals a DEA decision barring him from prescribing psilocybin, citing state and federal 'right to try' laws giving terminal patients access to experimental therapies.
The DEA argues against Aggarwal's prescribing of psilocybin due to its classification as a Schedule I narcotic under the Controlled Substances Act of 1970, despite patient demand supported by studies.
Aggarwal's cases before the 9th Circuit challenge DEA's restrictions on prescribing psilocybin and aim to have it rescheduled to allow therapy use, not just research.
Collection
[
|
...
]